{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T05:43:43Z","timestamp":1772689423834,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100032767","name":"Sichuan Medical Association","doi-asserted-by":"crossref","award":["S23008"],"award-info":[{"award-number":["S23008"]}],"id":[{"id":"10.13039\/100032767","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100032767","name":"Sichuan Medical Association","doi-asserted-by":"crossref","award":["S23008"],"award-info":[{"award-number":["S23008"]}],"id":[{"id":"10.13039\/100032767","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100032767","name":"Sichuan Medical Association","doi-asserted-by":"crossref","award":["S23008"],"award-info":[{"award-number":["S23008"]}],"id":[{"id":"10.13039\/100032767","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100032767","name":"Sichuan Medical Association","doi-asserted-by":"crossref","award":["S23008"],"award-info":[{"award-number":["S23008"]}],"id":[{"id":"10.13039\/100032767","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06596-4","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T07:58:50Z","timestamp":1759132730000},"page":"5521-5530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of EPOR-rearranged acute lymphoblastic leukemia with ruxolitinib: case reports and review of the literature"],"prefix":"10.1007","volume":"104","author":[{"given":"Yiling","family":"Dai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"11","key":"6596_CR1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D et al (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371(11):1005\u20131015. https:\/\/doi.org\/10.1056\/NEJMoa1403088","journal-title":"N Engl J Med"},{"issue":"5","key":"6596_CR2","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1038\/bcj.2016.28","volume":"13","author":"T Imamura","year":"2016","unstructured":"Imamura T, Kiyokawa N, Kato M et al (2016) Characterization of pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia with kinase fusions in Japan. Blood Cancer J 13(5):e419. https:\/\/doi.org\/10.1038\/bcj.2016.28","journal-title":"Blood Cancer J May"},{"key":"6596_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2020.151514","volume":"46","author":"W Liu","year":"2020","unstructured":"Liu W, Thakral B, Tang G, Wang W, Medeiros LJ, Konoplev S (2020) From the archives of MD Anderson cancer center: BCR-ABL1-like B acute lymphoblastic leukemia with IGH\/EPOR fusion. Ann Diagn Pathol 46:151514. https:\/\/doi.org\/10.1016\/j.anndiagpath.2020.151514","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"6596_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccell.2015.12.013","volume":"8","author":"I Iacobucci","year":"2016","unstructured":"Iacobucci I, Li Y, Roberts KG et al (2016) Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. Cancer Cell 8(2):186\u2013200. https:\/\/doi.org\/10.1016\/j.ccell.2015.12.013","journal-title":"Cancer Cell Feb"},{"issue":"1","key":"6596_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06485-7","volume":"9","author":"M Rusch","year":"2018","unstructured":"Rusch M, Nakitandwe J, Shurtleff S et al (2018) Clinical cancer genomic profiling by three-platform sequencing of whole genome, whole exome and transcriptome. Nat Commun 9(1):3962. https:\/\/doi.org\/10.1038\/s41467-018-06485-7","journal-title":"Nat Commun"},{"issue":"25","key":"6596_CR6","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1200\/jco.2012.47.6770","volume":"31","author":"BW Weston","year":"2013","unstructured":"Weston BW, Hayden MA, Roberts KG et al (2013) Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. J Clin Oncol 31(25):e413-416. https:\/\/doi.org\/10.1200\/jco.2012.47.6770","journal-title":"J Clin Oncol"},{"issue":"11","key":"6596_CR7","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.3324\/haematol.2013.095372","volume":"98","author":"E Lengline","year":"2013","unstructured":"Lengline E, Beldjord K, Dombret H, Soulier J, Boissel N, Clappier E (2013) Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica 98(11):e146\u2013e148. https:\/\/doi.org\/10.3324\/haematol.2013.095372","journal-title":"Haematologica Nov"},{"issue":"2","key":"6596_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX et al (2009) A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 10(2):125\u2013134. https:\/\/doi.org\/10.1016\/S1470-2045(08)70339-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"6596_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5858\/arpa.2019-0194-RA","volume":"144","author":"S Jain","year":"2020","unstructured":"Jain S, Abraham A (2020) BCR-ABL1-like B-acute lymphoblastic leukemia\/lymphoma: a comprehensive review. Arch Pathol Lab Med 144(2):150\u2013155. https:\/\/doi.org\/10.5858\/arpa.2019-0194-RA","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"6596_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1053\/j.seminhematol.2018.05.001","volume":"55","author":"M Khan","year":"2018","unstructured":"Khan M, Siddiqi R, Tran TH (2018) Philadelphia chromosome-like acute lymphoblastic leukemia: a review of the genetic basis, clinical features, and therapeutic options. Semin Hematol 55(4):235\u2013241. https:\/\/doi.org\/10.1053\/j.seminhematol.2018.05.001","journal-title":"Semin Hematol"},{"issue":"3","key":"6596_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/leu.2008.250","volume":"23","author":"LJ Russell","year":"2009","unstructured":"Russell LJ, De Castro DG, Griffiths M et al (2009) A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin. Leukemia 23(3):614\u2013617. https:\/\/doi.org\/10.1038\/leu.2008.250","journal-title":"Leukemia"},{"issue":"Aug","key":"6596_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.ccr.2012.06.005","volume":"14","author":"KG Roberts","year":"2012","unstructured":"Roberts KG, Morin RD, Zhang J et al (2012) Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22(2):153\u2013166. https:\/\/doi.org\/10.1016\/j.ccr.2012.06.005","journal-title":"Cancer Cell"},{"issue":"6","key":"6596_CR13","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s12185-016-2083-2","volume":"104","author":"K Sakamoto","year":"2016","unstructured":"Sakamoto K, Tanaka S, Tomoyasu C et al (2016) Development of acute lymphoblastic leukemia with IgH-EPOR in a patient with secondary erythrocytosis. Int J Hematol 104(6):741\u2013743. https:\/\/doi.org\/10.1007\/s12185-016-2083-2","journal-title":"Int J Hematol"},{"issue":"9","key":"6596_CR14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3760\/cma.j.issn.0253-2727.2018.09.014","volume":"14","author":"Q Yang","year":"2018","unstructured":"Yang Q, Shao HG, Liu HF et al (2018) [Ph-like acute lymphocytic leukemia with EPOR rearrangement: 2 cases report and literatures review]. Zhonghua Xue Ye Xue Za Zhi Sep 14(9):773\u2013775. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2018.09.014","journal-title":"Zhonghua Xue Ye Xue Za Zhi Sep"},{"issue":"10","key":"6596_CR15","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.3324\/haematol.2021.278697","volume":"106","author":"LM Niswander","year":"2021","unstructured":"Niswander LM, Loftus JP, Lainey \u00c9 et al (2021) Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica 106(10):2763\u20132767. https:\/\/doi.org\/10.3324\/haematol.2021.278697","journal-title":"Haematologica"},{"issue":"3","key":"6596_CR16","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/modpathol.2013.149","volume":"27","author":"JM Jaso","year":"2014","unstructured":"Jaso JM, Yin CC, Lu VW et al (2014) B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH\/EPOR: a clinically aggressive subset of disease. Mod Pathol 27(3):382\u2013389. https:\/\/doi.org\/10.1038\/modpathol.2013.149","journal-title":"Mod Pathol"},{"issue":"25","key":"6596_CR17","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/blood-2016-12-758979","volume":"129","author":"SC Reshmi","year":"2017","unstructured":"Reshmi SC, Harvey RC, Roberts KG et al (2017) Targetable kinase gene fusions in high-risk B-ALL: a study from the children\u2019s oncology group. Blood 129(25):3352\u20133361. https:\/\/doi.org\/10.1182\/blood-2016-12-758979","journal-title":"Blood"},{"issue":"19","key":"6596_CR18","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2017-06-743252","volume":"130","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Loh ML, Hunger SP (2017) Philadelphia chromosome-like acute lymphoblastic leukemia. Blood 130(19):2064\u20132072. https:\/\/doi.org\/10.1182\/blood-2017-06-743252","journal-title":"Blood"},{"issue":"4","key":"6596_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","volume":"35","author":"KG Roberts","year":"2017","unstructured":"Roberts KG, Gu Z, Payne-Turner D et al (2017) High frequency and poor outcome of Philadelphia Chromosome-Like acute lymphoblastic leukemia in adults. J Clin Oncol 35(4):394\u2013401. https:\/\/doi.org\/10.1200\/JCO.2016.69.0073","journal-title":"J Clin Oncol"},{"issue":"23","key":"6596_CR20","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1182\/blood-2009-08-239681","volume":"116","author":"RC Harvey","year":"2010","unstructured":"Harvey RC, Mullighan CG, Wang X et al (2010) Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116(23):4874\u20134884. https:\/\/doi.org\/10.1182\/blood-2009-08-239681","journal-title":"Blood"},{"issue":"1","key":"6596_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1200\/JCO.2017.76.0504","volume":"36","author":"SP Hunger","year":"2018","unstructured":"Hunger SP (2018) Integrated risk stratification using minimal residual disease and sentinel genetic alterations in pediatric acute lymphoblastic leukemia. J Clin Oncol 36(1):4\u20136. https:\/\/doi.org\/10.1200\/JCO.2017.76.0504","journal-title":"J Clin Oncol"},{"issue":"6","key":"6596_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00277-023-05241-2","volume":"102","author":"R Alghandour","year":"2023","unstructured":"Alghandour R, Sakr DH, Shaaban Y (2023) Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant-review article. Ann Hematol 102(6):1287\u20131300. https:\/\/doi.org\/10.1007\/s00277-023-05241-2","journal-title":"Ann Hematol"},{"issue":"27","key":"6596_CR23","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1200\/JCO.2014.55.4105","volume":"32","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Pei D, Campana D et al (2014) Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol 32(27):3012\u20133020. https:\/\/doi.org\/10.1200\/JCO.2014.55.4105","journal-title":"J Clin Oncol"},{"issue":"6","key":"6596_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1177\/0091270011405663","volume":"52","author":"JG Shi","year":"2012","unstructured":"Shi JG, Chen X, Emm T et al (2012) The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol 52(6):809\u2013818. https:\/\/doi.org\/10.1177\/0091270011405663","journal-title":"J Clin Pharmacol"},{"key":"6596_CR25","doi-asserted-by":"publisher","first-page":"106925","DOI":"10.1016\/j.leukres.2022.106925","volume":"121","author":"J Kolodrubiec","year":"2022","unstructured":"Kolodrubiec J, Kozlowska M, Irga-Jaworska N et al (2022) Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review. Leuk Res 121:106925. https:\/\/doi.org\/10.1016\/j.leukres.2022.106925","journal-title":"Leuk Res Oct"},{"issue":"6","key":"6596_CR26","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3324\/haematol.2020.270645","volume":"1","author":"JM Ribera","year":"2021","unstructured":"Ribera JM (2021) Philadelphia chromosome-like acute lymphoblastic leukemia. Still a pending matter. Haematologica 106(6):1514\u20131516. https:\/\/doi.org\/10.3324\/haematol.2020.270645","journal-title":"Haematologica Jun"},{"key":"6596_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112611","volume":"13","author":"K Klein","year":"2021","unstructured":"Klein K, Stoiber D, Sexl V, Witalisz-Siepracka A (2021) Untwining anti-tumor and immunosuppressive effects of JAK inhibitors-a strategy for hematological malignancies? Cancers (Basel) 13:2611. https:\/\/doi.org\/10.3390\/cancers13112611","journal-title":"Cancers (Basel)"},{"issue":"10","key":"6596_CR28","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.3324\/haematol.2021.278697","volume":"106","author":"LM Niswander","year":"2021","unstructured":"Niswander LM, Loftus JP, Lainey E et al (2021) Therapeutic potential of ruxolitinib and ponatinib in patients with EPOR-rearranged Philadelphia chromosome-like acute lymphoblastic leukemia. Haematologica 106(10):2763\u20132767. https:\/\/doi.org\/10.3324\/haematol.2021.278697","journal-title":"Haematologica"},{"issue":"10","key":"6596_CR29","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/pbc.25575","volume":"62","author":"ML Loh","year":"2015","unstructured":"Loh ML, Tasian SK, Rabin KR et al (2015) A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: a children\u2019s oncology group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer 62(10):1717\u20131724. https:\/\/doi.org\/10.1002\/pbc.25575","journal-title":"Pediatr Blood Cancer"},{"key":"6596_CR30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2011-12-389932","volume":"120","author":"SK Tasian","year":"2012","unstructured":"Tasian SK, Doral MY, Borowitz MJ et al (2012) Aberrant STAT5 and PI3K\/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia. Blood 120:833\u2013842. https:\/\/doi.org\/10.1182\/blood-2011-12-389932","journal-title":"Blood"},{"issue":"2","key":"6596_CR31","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1182\/blood-2016-05-707653","volume":"2017\u201301","author":"SK Tasian","year":"2017","unstructured":"Tasian SK, Teachey DT, Li Y et al (2017) Potent efficacy of combined PI3K\/mTOR and JAK or ABL Inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood 192(2):177\u2013187. https:\/\/doi.org\/10.1182\/blood-2016-05-707653","journal-title":"Blood"},{"issue":"18","key":"6596_CR32","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1182\/blood-2011-05-354266","volume":"3","author":"V Torrano","year":"2011","unstructured":"Torrano V, Procter J, Cardus P, Greaves M, Ford AM (2011) ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor. Blood 118(18):4910\u20134918. https:\/\/doi.org\/10.1182\/blood-2011-05-354266","journal-title":"Blood Nov"},{"key":"6596_CR33","doi-asserted-by":"publisher","first-page":"942053","DOI":"10.3389\/fcell.2022.942053","volume":"10","author":"CE Downes","year":"2022","unstructured":"Downes CE, McClure BJ, McDougal DP et al (2022) JAK2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies. Front Cell Dev Biol 10:942053. https:\/\/doi.org\/10.3389\/fcell.2022.942053","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"6596_CR34","doi-asserted-by":"publisher","first-page":"e14024","DOI":"10.1111\/petr.14024","volume":"25","author":"N Bayram","year":"2021","unstructured":"Bayram N, Yaman Y, \u00d6zdilli K et al (2021) Clinical efficacy of ruxolitinib monotherapy and haploidentical hematopoeitic stem cell transplantation in a child with Philadelphia Chromosome-like relapsed\/refractory acute lymphoblastic leukemia. Pediatr Transplant 25(4):e14024. https:\/\/doi.org\/10.1111\/petr.14024","journal-title":"Pediatr Transplant"},{"issue":"3","key":"6596_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.clml.2014.08.003","volume":"15","author":"N Pemmaraju","year":"2015","unstructured":"Pemmaraju N, Kantarjian H, Kadia T et al (2015) A Phase I\/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 15(3):171\u2013176","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Suppl","key":"6596_CR36","doi-asserted-by":"publisher","first-page":"S124","DOI":"10.1016\/j.clml.2016.02.016","volume":"16","author":"J Mascarenhas","year":"2016","unstructured":"Mascarenhas J (2016) A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms. Clin Lymphoma Myeloma Leuk 16(Suppl):S124-129. https:\/\/doi.org\/10.1016\/j.clml.2016.02.016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"15","key":"6596_CR37","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P et al (2010) Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115(15):3109\u20133117. https:\/\/doi.org\/10.1182\/blood-2009-04-214957","journal-title":"Blood"},{"issue":"2","key":"6596_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrd3264","volume":"10","author":"A Quintas-Cardama","year":"2011","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S (2011) Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov 10(2):127\u2013140. https:\/\/doi.org\/10.1038\/nrd3264","journal-title":"Nat Rev Drug Discov"},{"key":"6596_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0417-z","volume":"10","author":"S Verstovsek","year":"2017","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2017) Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol 10(1):55. https:\/\/doi.org\/10.1186\/s13045-017-0417-z","journal-title":"J Hematol Oncol"},{"issue":"2","key":"6596_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1093\/ajhp\/zxab396","volume":"5","author":"Ruxolitinib Phosphate","year":"2022","unstructured":"Ruxolitinib Phosphate (2022) Am J Health Syst Pharm 79(2):6\u20139. https:\/\/doi.org\/10.1093\/ajhp\/zxab396","journal-title":"Am J Health Syst Pharm Jan"},{"issue":"9","key":"6596_CR41","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783","journal-title":"N Engl J Med"},{"issue":"14","key":"6596_CR42","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N Gokbuget","year":"2018","unstructured":"Gokbuget N, Dombret H, Bonifacio M et al (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531. https:\/\/doi.org\/10.1182\/blood-2017-08-798322","journal-title":"Blood"},{"issue":"5","key":"6596_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M et al (2018) Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 378(5):449\u2013459. https:\/\/doi.org\/10.1056\/NEJMoa1709919","journal-title":"N Engl J Med"},{"issue":"11","key":"6596_CR44","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1080\/10428194.2022.2090550","volume":"63","author":"GF Xu","year":"2022","unstructured":"Xu GF, Liu LM, Wang M et al (2022) Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective analysis from a single large center in China. Leuk Lymphoma 63(11):2652\u20132662. https:\/\/doi.org\/10.1080\/10428194.2022.2090550","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06596-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06596-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06596-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:18:57Z","timestamp":1763194737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06596-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":44,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6596"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06596-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of West China Second Hospital of Sichuan University. Written informed consent to participate in this study was provided by the participants\u2019 legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent for publication was obtained from the patients\u2019 legal guardians.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}